Belite Bio Announces Late-Breaking Presentation At The American Academy Of Ophthalmology 2022 Annual Meeting

Belite Bio, Inc (NASDAQ:BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today announced that the 1-year interim data from the 2-year Phase

Belite Bio, Inc (NASDAQ:BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today announced that the 1-year interim data from the 2-year Phase 1b/2 trial of LBS-008 in adolescent STGD1 will be presented at the “Late Breaking Development” session at the American Academy of Ophthalmology Annual Meeting (AAO 2022) being held September 30 – October 3, 2022 in Chicago.

Details of the presentation are as follows:

Title: A 2-year Phase 1b/2 Study of the Safety and Tolerability of Tinlarebant in Adolescent STGD1 Subjects: Interim Findings

Abstract Number: 30071744

Section: Section X, Late Breaking Developments, Part II

Date and Time: Saturday, Oct 1, 2022 – 9:20 AM – 9:25 AM (Central Daylight Time)

Location: McCormick Place – Arie Crown, Chicago

Presenting Author: John Grigg, MBBS

For more information about the AAO 2022 annual meeting please visit: https://www.aao.org/annual-meeting.

About LBS-008

LBS-008 is a novel oral therapy intended as an early intervention to prevent the buildup of toxins in the eye that cause STGD1 and contribute to Dry AMD. These toxins are by-products of vitamin A in the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. LBS-008 works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for transport of retinol into the eye. By modulating the amount of retinol entering the eye, LBS-008 reduces the formation of vitamin A-based toxins which have been implicated in STGD1 and Dry AMD in order to maintain the health of retinal tissues. LBS-008 has been granted Fast Track Designation, Rare Pediatric Disease Designation in the U.S., and Orphan Drug Designation in the U.S. and Europe for the treatment of STGD1.

Total
0
Shares
Related Posts